Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1 -> 3)-beta-D-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis-论文-万方医学网

Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1 -> 3)-beta-D-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis

导出原文传递

翻译打印收藏纠错

作者： Petraitis, Vidmantas ^[1] ; Petraitiene, Ruta ^[2] ; Katragkou, Aspasia ^[3] ; Maung, Bo Bo Win ; Naing, Ethan ; Kavaliauskas, Povilas ; Barat, Stephen ; Borroto-Esoda, Katyna ; Azie, Nkechi ; Angulo, David ; Walsh, Thomas J.

作者单位： Cornell Univ, Dept Med, Transplantat Oncol Infect Dis Program, Div Infect Dis,Weill Cornell Med ^[1] Scynexis Inc, Jersey City, NY USA ^[2] Ohio State Univ, Nationwide Childrens Hosp, Pediat Infect Dis Dept, Columbus, OH 43210 USA ^[3]

关键词 combination therapy ibrexafungerp (SCY-078)isavuconazole pulmonary aspergillosis rabbits

发布时间 2022-10-12

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除